Comparing Shuttle Pharmaceuticals (NASDAQ:SHPH) & Allergy Therapeutics (OTCMKTS:AGYTF)

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Allergy Therapeutics (OTCMKTS:AGYTF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Shuttle Pharmaceuticals and Allergy Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1	0	0	0	1.00
Allergy Therapeutics	0	0	0	0	0.00

Profitability

This table compares Shuttle Pharmaceuticals and Allergy Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-444.90%	-188.81%
Allergy Therapeutics	N/A	N/A	N/A

Valuation & Earnings

This table compares Shuttle Pharmaceuticals and Allergy Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72 million	($11.84)	-0.07
Allergy Therapeutics	$71.22 million	1.06	-$51.94 million	N/A	N/A

Shuttle Pharmaceuticals has higher earnings, but lower revenue than Allergy Therapeutics.

Volatility and Risk

Shuttle Pharmaceuticals has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Allergy Therapeutics has a beta of 12.76, meaning that its stock price is 1,176% more volatile than the S&P 500.

Insider and Institutional Ownership

4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

About Allergy Therapeutics

Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.